University of Texas's MD Anderson Cancer: Venetoclax Combination Therapies Found Effective Against Challenging Subtypes of Acute Myeloid Leukemia
December 14, 2021
December 14, 2021
HOUSTON, Texas, Dec. 14 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Studies presented at the ASH conference highlight improved outcomes in patients with AML
* * *
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory . . .
* * *
Studies presented at the ASH conference highlight improved outcomes in patients with AML
* * *
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory . . .